Migraine trials in Japan

In Japan 7 Also abroad 249

7 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Where
Abeno-ku Osaka-shi, Higashinada-ku Kobe-shi, Hiroshima, Kagoshima, Kasuga-shi, Kiryu-shi, Mito, Naniwa-ku, Nishinomiya-shi, Shibuya-ku, Shinjuku-ku, Taihaku-ku Sendai-shi
Age
6 years to 17 years
People
2,100 worldwide
Run by
Pfizer
See details and how to joinNCT04649242 · EU 2024-512743-23-00
Phase 3Taking people
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Where
Abeno-ku Osaka-shi, Chuo-ku Saitama-shi, Higashinada-ku Kobe-shi, Kagoshima, Kasuga-shi, Kiryu-shi, Kochi, Mito, Naniwa-ku, Nishinomiya-shi, Shibuya-ku, Shinjuku-ku, Taihaku-ku Sendai-shi
Age
6 years to 17 years
People
640 worldwide
Run by
Pfizer
See details and how to joinNCT05156398 · EU 2024-512382-13-00
Phase 3Taking people
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Where
Kagoshima, Kai, Kobe, Kochi, Osaka, Shibuya-ku, Shinjuku-ku, Tendo-shi
Age
12 years to 17 years
People
420 worldwide
Run by
AbbVie
See details and how to joinNCT06810505 · EU 2024-513836-28-00
Phase 3Taking people
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Where
Kobe, Kochi, Kyoto, Nishinomiya, Osaka, Sendai, Shinjuku-ku
Age
6 years to 17 years
People
450 worldwide
Run by
AbbVie
See details and how to joinNCT05711394 · EU 2022-501100-94-00
Phase 3Taking people
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Where
Kagoshima, Kai, Kobe, Kyoto-shi Shimogyo-ku, Sendai, Shibuya-ku
Age
18 years to 45 years
People
723 worldwide
Run by
Pfizer
See details and how to joinNCT06641466 · EU 2024-517121-10-00
No phaseTaking people
Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use
Where
Osaka
Age
18 years and over
People
1,000
Run by
Otsuka Pharmaceutical Co., Ltd.
See details and how to joinNCT05342493
Phase 3Enrolling by invitation
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
Where
Kobe, Kochi, Kyoto, Nishinomiya-shi, Osaka, Sendai, Shinjuku-ku
Age
6 years to 17 years
People
650 worldwide
Run by
AbbVie
See details and how to joinNCT05707949 · EU 2022-501099-24-00